In an interview with ONCOLOGY®, Evan B. Bryson, PharmD, BCOP, offers a comprehensive review of real-world treatment considerations of amivantamab as therapy for patients with non–small cell lung cancer.
Evan B. Bryson, PharmD, BCOP
Advertisement
Articles by Evan B. Bryson, PharmD, BCOP
Advertisement
Latest Updated Articles
Expert Commentary on the Product Profile of Amivantamab-vmjwMarch 12th 2022
Advertisement
Advertisement
Trending on CancerNetwork
1
Melanoma Vaccine Receives FDA Fast Track Designation
2
NCCN Guidelines Recommend Taletrectinib for ROS1+ NSCLC Subtype
3
Targeting NAMPT and KRAS in Pancreatic Ductal Adenocarcinoma
4
145 Racial Differences in Outcomes and Health Care Utilization Among Patients With HR-Positive, HER2-Negative Metastatic Breast Cancer Treated With CDK4/6 Inhibitors: A Real-World Analysis
5